SRTAHealthcare · Medical Care FacilitiesSRTA Stock Forecast: Strata Critical Medical, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Strata Critical Medical, Inc. hold a median 12-month price target of $8.75 — +57.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 57 of 100 as at 1 Aug 2026 — in the upper half.
SRTA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Strata Critical Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (94): Analysts have, on balance, been raising their forecasts.
Accruals (15): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
The rank is the raw material. Whether the rules would actually own Strata Critical Medical, Inc. — and when they’d sell — is the membership.
SRTA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SRTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +57.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Mar 2026 | B. Riley Securities | Initiates | Buy | $8.00 |
| 25 Mar 2026 | Craig-Hallum | Initiates | Buy | $8.00 |
| 2 Dec 2025 | Lake Street | Assumes | Buy | $8.00 |
| 17 Sept 2025 | Lake Street | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SRTA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Strata Critical Medical, Inc. (SRTA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 10.5×
- Price / sales
- 1.9×
- Price / book
- 1.5×
- EV / EBITDA
- −3454.9×
Cheaper than 58% of US stocks
Cheaper than 54% of US stocks
Cheaper than 55% of US stocks
Cheaper than 99% of US stocks
- Revenue growth (YoY)
- 87.4%
- Earnings growth (YoY)
- 24.1%
- Gross margin
- 21.0%
- Operating margin
- −2.8%
- Net margin
- 20.6%
Higher than 92% of US stocks
Higher than 65% of US stocks
Higher than 23% of US stocks
Higher than 32% of US stocks
Higher than 83% of US stocks
- Return on equity
- −6.4%
- Return on assets
- −1.9%
- Dividend yield
- —
Higher than 38% of US stocks
Higher than 37% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SRTA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRTA appears on the weeks it earns a place.
Frequently asked questions about SRTA stock
What is the SRTA stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Strata Critical Medical, Inc. have a median 12-month price target of $8.75, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SRTA stock a buy right now?
Of the 4 analysts covering Strata Critical Medical, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Strata Critical Medical, Inc. 57 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SRTA?
As at 1 Aug 2026, Strata Critical Medical, Inc. ranks 57 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).
Will SRTA stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +57.7% from the last close, and Ticker Nerd's factor model ranks Strata Critical Medical, Inc. 57 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SRTA stock forecast for 2030?
No analyst covering Strata Critical Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.
How has SRTA stock performed over the past year?
Strata Critical Medical, Inc. returned +46.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Strata Critical Medical, Inc. do?
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States.
About Strata Critical Medical, Inc.
Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.
CEO Ms. Melissa M. Tomkiel J.D. · 327 employees · United States · https://www.stratacritical.com